HIV and urethritis: time required for antiretroviral therapy to suppress HIV in semen.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 11 2023
15 11 2023
Historique:
medline:
26
10
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
To examine the time required to suppress HIV in the genital tract with antiretroviral therapy (ART) in men with urethritis. An observational cohort study. Men with HIV and urethritis not on ART were enrolled at an STI clinic in Malawi and offered to initiate ART. Blood and semen samples were collected pretreatment and at 1, 2, 4, 8, 12 and 24 weeks posturethritis treatment. Median viral loads (VLs) were calculated by ART initiation groups: 'within 1 week', 'between 1 and 4 weeks' and 'no ART before 4 weeks', based on the men's choice about whether or not to initiate ART. The presence of ART at each visit was confirmed by bioanalytical methods. Between January 2017 and November 2018, 74 men presented with urethritis and HIV and were confirmed ART naive. The median age was 32 years. Forty-one (55% of men) initiated ART within 1 week; 12 (16%) between 1 and 4 weeks; and 21 (28%) did not initiate ART by week 4. Within the 1 week group, median VL was suppressed within 4 weeks in both semen and blood. Among the 1-4 weeks group, VL was suppressed within 4 weeks in semen and 5 weeks in blood. Among the no ART before 4 weeks group, VL in semen declined within the first 4 weeks but remained unsuppressed through week 24, and there was no significant decline in blood HIV. Treatment of urethritis and prompt initiation of ART with counseling for safer sex for at least one month is a critical measure to reduce transmission of HIV.
Identifiants
pubmed: 37534689
doi: 10.1097/QAD.0000000000003679
pii: 00002030-990000000-00319
pmc: PMC10621634
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Observational Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2233-2238Subventions
Organisme : NIAID NIH HHS
ID : T32 AI070114
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI114320
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010060
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK108424
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
AIDS. 2000 Jan 28;14(2):117-21
pubmed: 10708281
Lancet. 2019 Jun 15;393(10189):2428-2438
pubmed: 31056293
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
Sci Transl Med. 2011 Apr 6;3(77):77ra29
pubmed: 21471433
Clin Infect Dis. 2021 Oct 5;73(7):e2000-e2004
pubmed: 33033831
Indian J Sex Transm Dis AIDS. 2020 Jul-Dec;41(2):162-168
pubmed: 33817588
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):579-84
pubmed: 27070123
Eur J Med Res. 2022 Jan 13;27(1):9
pubmed: 35027093
Sex Transm Infect. 2005 Apr;81(2):120-3
pubmed: 15800087
AIDS. 2001 May 4;15(7):837-45
pubmed: 11399956
Lancet. 1997 Jun 28;349(9069):1868-73
pubmed: 9217758
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
AIDS. 2001 Mar 30;15(5):621-7
pubmed: 11317000
Sex Transm Dis. 1995 May-Jun;22(3):145-8
pubmed: 7652655
Nat Med. 2021 Nov;27(11):1893-1898
pubmed: 34711975
AIDS. 2009 Jul 17;23(11):1397-404
pubmed: 19381076
Braz J Infect Dis. 2021 Jan-Feb;25(1):101044
pubmed: 33417851
J Virol. 1997 Aug;71(8):6271-5
pubmed: 9223532
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
PLoS One. 2013;8(2):e55747
pubmed: 23418455